Shenzhen Fibro Miracle Biomedical Technology Co., Ltd. has just announced the successful completion of its A+ round of financing, securing nearly 100 million yuan, with Legend Capital taking the lead. Over the past year, Fibro Miracle has impressively secured two rounds of financing, each nearing the 100 million yuan mark.

The funds raised in this round will be channeled primarily towards fueling its global business expansion and setting up a fully automated separation and purification technology platform. Building on its proprietary core technologies, Fibro Miracle made a significant breakthrough in 2021 by launching its ultrasonic nanofiltration fully automated exosome separation and purification technology. It also developed the EXODUS fully automated exosome purification platform, which boasts the world's pioneering membrane vibration separation technology.

The company has crafted a comprehensive product lineup that spans the entire spectrum from research to industrialization. The recently introduced EXODUS M-600 is a testament to its ongoing technological advancements and engineering innovations. Over the past three years, the EXODUS platform has seen over 300 installations, served more than 500 clients worldwide, and found applications across a diverse range of fields.

As exosome therapy progresses into advanced clinical trial stages and the industry's industrialization picks up pace, Fibro Miracle's technology platform has evolved to encompass the separation and purification of various nanoparticle types. Looking to the future, the company aims to drive the seamless integration of physical AI with nanoparticle separation and purification technologies, paving the way for modular, integrated solutions.

Legend Capital expresses strong confidence in Fibro Miracle's growth prospects and pledges its full support for the company's technological transformation and global market expansion.